Abstract
1. Stop injection/infusion immediately
2. Get extravasation kit
3. Put on (sterile) gloves
4. Replace infusion lead or syringe with 5 ml disposable syringe and aspirate slowly as much as possible of the extravasated drug; Cave! do not exert pressure on extravasation area
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Original articles
Bertelli G, Gozza A, Forno GB, et al: Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: a prospective clinical study. J Clin Oncol 13: 2851–2855, 1995.
Marnocha RS, Hutson PR: Intradermal carboplatin and ifosfamide extravasation in the mouse. Cancer 70: 850–853, 1992.
Bertelli G, Dini D, Forno G, et al: Dimethylsulphoxide and cooling after extravasation of antitumour agents. Lancet 341: 1098–1099, 1993.
Brock N, Hilgard P, Peukert M, et al:Basis and new developments in the field of oxazaphosphorines. Cancer Invest 6: 513–532, 1988.
Mateu J, Alzamora M, Franco M, et al: Ifosfamide extravasation. Ann Pharmacother 28: 1243–1244, 1994.
Whang SW, Lee SH, Elias PM, et al: Intralesional steroids reduce inflammation from extravasated chemotherapeutic agents. Br J Dermatol 145: 680–682, 2001.
Krämer I: Zehn Jahre Dokumentation von Zytostatika-Paravasat-Ereignissen: Auswertung von 175 Paravasate-Dokumentationen. Krankenhauspharmazie 23: 269–274, 2002.
Secondary literature
Summary of product characteristics Holoxan® (Germany), Baxter, January 2002.
Stanley A: Managing complications of chemotherapy administration. In: Allwood M, Stanley A, Wright P (eds) The Cytotoxics Handbook. Radcliffe Medical Press, 4th edition: 119–193, 2002.
Krämer I, Stützle M: Zytostatika-Paravasation – Wie ist vorzugehen? Krankenhauspharmazie 23: 261–268, 2002.
Ignoffo RJ, Friedman MA: Therapy of local toxicities caused by extravasation of cancer chemotherapeutic drugs. Cancer Treat Rev 7: 17–27, 1980.
Gain M, Melzer S, Meyer-Jürshof A, et al: Allgemeiner Teil: Behandlung von Paravasaten. In: Gain M, et al (eds) ADKA–Zytostatika-Handbuch, Pharmazeutisch-wissenschaftliche Monographien. Verlag Heiner Biller, Vol 1, 2nd edition: A42–44, 1997.
Bertelli G: Prevention and management of extravasation of cytotoxic drugs. Drug Safety 12: 45–255, 1995.
Mullin S, Beckwith MC, Tyler LS: Prevention and management of antineoplastic extravasation injury. Hosp Pharm 35: 57–76, 2000.
Dorr RT, Von Hoff DD: Drug monographs: ifosfamide. In: Dorr RT, Von Hoff DD (eds) Cancer Chemotherapy Handbook. Appleton & Lange, 2nd edition: 558–563, 1994.
Barth J: Paravasate und deren Behandlung. In: Barth J (ed) -Zytostatika-Herstellung in der Apotheke. Deutscher Apotheker Verlag, chapter VI-3: 1–9, 2000.
Gain M, Melzer S, Meyer-Jürshof A, et al: Ifosfamid: Behandlung von Paravasaten. In: Gain M, et al (eds) ADKA-Zytostatika-Handbuch, Pharmazeutisch-wissenschaftliche Monographien. Verlag Heiner Biller, vol 5: 26, 2001.
Ener RA, Meglathery SB, Styler M: Extravasation of systemic hemato-oncological therapies. Ann Oncol 15: 858–862, 2004.
Jordan K, Grothe W, Schmoll HJ:Paravasation von Zytostatika: Prävention und Therapie. Dtsch Med Wochenschr 130: 33–37, 2005.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer-Verlag/Wien
About this chapter
Cite this chapter
Mader, I., Fürst-Weger, P., Mader, R., Nogler-Semenitz, E., Wassertheurer, S. (2010). Ifosfamide. In: Extravasation of Cytotoxic Agents. Springer, Vienna. https://doi.org/10.1007/978-3-211-88893-3_40
Download citation
DOI: https://doi.org/10.1007/978-3-211-88893-3_40
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-88889-6
Online ISBN: 978-3-211-88893-3
eBook Packages: MedicineMedicine (R0)